Q-omics provides the consensus-scored TRAJ7 profile across patient tissues and cancer cell-line models. TRAJ7 expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in SKCM. Among the 18 cancer types available for tumor–normal comparison, TRAJ7 is differentially expressed in 5, with the highest sampling consensus in LUSC. Additionally, TRAJ7 RNA expression shows 13,386 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight SKCM, LUSC, and LSCC as cancer lineages where TRAJ7 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRAJ7 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRAJ7 survival associations across molecular data types. TRAJ7 RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRAJ7 RNA expression–survival associations across cancer types. High TRAJ7 expression shows unfavorable associations in KIRC, BLCA, LUSC and THCA, but favorable associations in SKCM and OV. The SKCM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify SKCM as the clearest survival context for TRAJ7 RNA expression.
This table summarizes TRAJ7 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for TRAJ7. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRAJ7 shows lower tumor expression in LUSC and COAD and higher tumor expression in KIRC, BRCA and LUAD. The LUSC box plot shows higher TRAJ7 RNA expression in normal versus tumor tissue (log2 FC = −0.690, t-test p = .015).
This table shows molecular features associated with TRAJ7 in patient tissues and cancer cell lines. In patient samples, TRAJ7 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
